Key result
GPR55 activation worsens macrophage lipid accumulation and blocks cholesterol efflux, an effect counteracted by cannabidiol.
Answers are grounded in this paper and cite their sources.
The G protein-coupled receptor GPR55 has been proposed as a new cannabinoid receptor associated with bone remodelling, nervous system excitability, vascular homeostasis as well as in several pathophysiological conditions including obesity and cancer. However, its physiological role and underlying mechanism remain unclear. In the present work, we demonstrate for the first time its presence in human macrophages and its increased expression in ox-LDL-induced foam cells. In addition, pharmacological activation of GPR55 by its selective agonist O-1602 increased CD36- and SRB-I-mediated lipid accumulation and blocked cholesterol efflux by downregulating ATP-binding cassette (ABC) transporters ABCA1 and ABCG1, as well as enhanced cytokine- and pro-metalloprotease-9 (pro-MMP-9)-induced proinflammatory responses in foam cells. Treatment with cannabidiol, a selective antagonist of GPR55, counteracted these pro-atherogenic and proinflammatory O-1602-mediated effects. Our data suggest that GPR55 could play deleterious role in ox-LDL-induced foam cells and could be a novel pharmacological target to manage atherosclerosis and other related cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Lanuti et al. (2015) studied Atherosclerosis (in vitro). O-1602 (GPR55 agonist) and Cannabidiol was evaluated on Lipid accumulation, cholesterol efflux, and inflammatory responses in oxLDL-induced foam cells. Pharmacological activation of GPR55 by O-1602 exacerbated lipid accumulation and blocked cholesterol efflux in human macrophages, effects that were counteracted by the antagonist cannabidiol.
Synapse has enriched 10 related papers. Consider them for comparative context: